AUAUniversity Podcast Series: Episode No. 94
PARP Inhibitors: Assessing the Clinical Trial Landscape
This educational series is supported by independent educational grants from AstraZeneca and Merck.
Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion.
Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.
Upon completion of this activity, participants will be able to:
- Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition.
- Discuss the current clinical trials associated with PARP inhibitors.
- Describe the patient populations associated with each trial.
- State the clinical outcomes for each trial.
Course Director: Ashley Ross, MD, PhD
Faculty: Emmanuel Antonarakis, MD
David Vanderweele, MD,PHD